PRECIRIX® is a clinical-stage biotechnology firm focused on creating revolutionary targeted radiopharmaceuticals based on camelid single domain antibody fragments to improve the lives of cancer patients.
While expanding and broadening its oncology portfolio, the company is moving its main product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive cancers.
PRECIRIX's technology platform enables a theragnostic approach, in which the same molecule is used for patient selection (imaging) as well as therapy.
PRECIRIX® is a clinical-stage biotechnology firm focused on creating revolutionary targeted radiopharmaceuticals based on camelid single domain antibody fragments to improve the lives of cancer patients.
While expanding and broadening its oncology portfolio, the company is moving its main product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive cancers.
PRECIRIX's technology platform enables a theragnostic approach, in which the same molecule is used for patient selection (imaging) as well as therapy.
